Gilbert Cisneros Buys Shares of PCVX $PCVX
Key Points
- Gilbert Cisneros bought Vaxcyte, Inc. ($PCVX) stock ($1,001 - $15,000).
- The trade was disclosed by a member of the House.
- $PCVX last traded around $47.46.
Gilbert Cisneros vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Gilbert Cisneros, a member of the House, bought $1,001 - $15,000 of Vaxcyte, Inc. ($PCVX) stock on 2026-05-12, according to a periodic transaction report filed under the STOCK Act. Disclosures are filed after the trade and reflect a dollar range, not an exact amount.
Vaxcyte, Inc. ($PCVX) Stock
Vaxcyte, Inc. Earnings
Analysts Set New Price Targets
About Vaxcyte, Inc.
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
See Also
This instant news alert was generated by automated narrative technology and financial data from Opentrades and public regulatory filings. It is for informational purposes only and is not financial advice.